BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 27252259)

  • 1. Advances in the treatment of cutaneous lupus erythematosus.
    Kuhn A; Landmann A; Wenzel J
    Lupus; 2016 Jul; 25(8):830-7. PubMed ID: 27252259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive review of immune-mediated dermatopathology in systemic lupus erythematosus.
    Li Q; Wu H; Liao W; Zhao M; Chan V; Li L; Zheng M; Chen G; Zhang J; Lau CS; Lu Q
    J Autoimmun; 2018 Sep; 93():1-15. PubMed ID: 30017673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous lupus erythematosus: issues in diagnosis and treatment.
    Walling HW; Sontheimer RD
    Am J Clin Dermatol; 2009; 10(6):365-81. PubMed ID: 19824738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The classification and diagnosis of cutaneous lupus erythematosus.
    Kuhn A; Landmann A
    J Autoimmun; 2014; 48-49():14-9. PubMed ID: 24486120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmune Skin Conditions: Cutaneous Lupus Erythematosus.
    Foulke G; Helm LA; Clebak KT; Helm M
    FP Essent; 2023 Mar; 526():25-36. PubMed ID: 36913660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological therapies in the treatment of cutaneous lupus erythematosus.
    Presto JK; Hejazi EZ; Werth VP
    Lupus; 2017 Feb; 26(2):115-118. PubMed ID: 27687023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous lupus erythematosus: diagnosis and management.
    Fabbri P; Cardinali C; Giomi B; Caproni M
    Am J Clin Dermatol; 2003; 4(7):449-65. PubMed ID: 12814335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs for discoid lupus erythematosus.
    Jessop S; Whitelaw DA; Delamere FM
    Cochrane Database Syst Rev; 2009 Oct; (4):CD002954. PubMed ID: 19821298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic implications of active discoid lupus erythematosus and malar rash at the time of diagnosis of systemic lupus erythematosus: Results from a prospective cohort study.
    Drucker AM; Su J; Mussani F; Siddha SK; Gladman DD; Urowitz MB
    Lupus; 2016 Apr; 25(4):376-81. PubMed ID: 26453664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous lupus erythematosus: a review.
    Patel P; Werth V
    Dermatol Clin; 2002 Jul; 20(3):373-85, v. PubMed ID: 12170873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers.
    Carter LM; Wigston Z; Laws P; Vital EM
    Br J Dermatol; 2023 Jul; 189(2):210-218. PubMed ID: 36944572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in cytokines in cutaneous and systemic lupus erythematosus.
    Mikita N; Ikeda T; Ishiguro M; Furukawa F
    J Dermatol; 2011 Sep; 38(9):839-49. PubMed ID: 21767292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into the progression from cutaneous lupus to systemic lupus erythematosus.
    Zhou W; Wu H; Zhao M; Lu Q
    Expert Rev Clin Immunol; 2020 Aug; 16(8):829-837. PubMed ID: 32746644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of cutaneous lupus erythematosus.
    Callen JP
    Med Clin North Am; 1982 Jul; 66(4):795-805. PubMed ID: 7098619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus.
    Quelhas da Costa R; Aguirre-Alastuey ME; Isenberg DA; Saracino AM
    JAMA Dermatol; 2018 Dec; 154(12):1432-1440. PubMed ID: 30383114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with Dapsone.
    Neri R; Mosca M; Bernacchi E; Bombardieri S
    Lupus; 1999; 8(3):240-3. PubMed ID: 10342718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Anifrolumab in Refractory Cutaneous Manifestations of Lupus Erythematosus: A Case Series and Literature Review.
    Khan MA; Khan FH; Khan HB; Saadeh C; Davey N
    Cureus; 2023 May; 15(5):e39553. PubMed ID: 37378095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel biological therapeutic approaches to cutaneous lupus erythematosus.
    Tayer-Shifman OE; Rosen CF; Wakani L; Touma Z
    Expert Opin Biol Ther; 2018 Oct; 18(10):1041-1047. PubMed ID: 30118337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenetics of cutaneous lupus erythematosus.
    Hersh AO; Arkin LM; Prahalad S
    Curr Opin Pediatr; 2016 Aug; 28(4):470-5. PubMed ID: 27386968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.